ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), a biopharmaceutical company, is focused on utilizing innovative technology to stimulate drug discovery and clinical development of novel treatments for central nervous system disorders. The company is currently developing a portfolio of its four most advanced product candidates, all of which originate from discoveries made using ACADIA’s proprietary drug discovery platform. For further information, visit the Company’s web site at www.acadia-pharm.com.
- 18 years ago
QualityStocks
ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Belden Inc. (NYSE: BDC) To Acquire RUCKUS Networks for $1.85 Billion
Belden (NYSE: BDC) announced it has entered into a definitive agreement to acquire RUCKUS Networks from Vistance Networks for approximately $1.85…
-
From Capital to Catalysts: Canamera Energy Metals Corp.’s (CSE: EMET) (OTCQB: EMETF) $10M Raise Sets the Stage for Rare Earth Exploration Momentum
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)and may include paid…
-
Forward Industries Inc. (NASDAQ: FWDI) Adds Digital Asset and Traditional Finance Executive Mark Brazier as Chief Financial Officer
Forward Industries has appointed experienced financial executive Mark Brazier to serve as Chief Financial Officer.…